Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors

  • Authors:
    • Yoshihiko Taniguchi
    • Akihiro Tamiya
    • Kenji Nakahama
    • Yoko Naoki
    • Masaki Kanazu
    • Naoki Omachi
    • Kyoichi Okishio
    • Takahiko Kasai
    • Shinji Atagi
  • View Affiliations

  • Published online on: October 3, 2017     https://doi.org/10.3892/ol.2017.7125
  • Pages:7589-7596
Metrics: PDF 0 views | HTML 0 views
0

Abstract

The aim of the present study was to analyze the impact of metastatic status on the prognosis of epithelial growth factor receptor (EGFR) mutation‑positive patients with non‑small cell lung cancer (NSCLC) treated with first‑generation EGFR‑tyrosine kinase inhibitors (TKIs). A total of 178 EGFR mutation‑positive patients with stage IIIB‑IV and relapsed NSCLC who were treated with gefitinib or erlotinib as the first‑line treatment were enrolled in the present study. Metastatic status, progression‑free survival (PFS), overall survival (OS) and treatment‑response rates were investigated. The association between the number of metastatic organ sites and patient prognosis was also investigated. The median age at the time of treatment was 72 (range, 39‑91) years. A total of 168 patients had adenocarcinoma; 156 were treated with gefitinib. Patients with brain metastases, bone metastases, liver metastases and pleural effusion exhibited a significantly reduced PFS and OS time in the univariate analysis, compared with patients without each of these symptoms. In the multivariate analysis, bone metastasis was associated with a poorer PFS (hazard ratio, 2.11; 95% confidence interval, 1.44‑3.09; P<0.001) and brain metastasis was associated with a poorer OS (hazard ratio, 2.41; 95% confidence interval, 1.46‑3.95; P<0.001). No association was observed between metastatic status and treatment response rates. Higher numbers of different sites of organ metastases were associated with significantly poorer PFS and OS. Bone, brain metastasis and higher numbers of metastatic organ sites are negative prognostic factors for EGFR mutation‑positive NSCLC patients treated with first‑generation EGFR‑TKIs.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Taniguchi, Y., Tamiya, A., Nakahama, K., Naoki, Y., Kanazu, M., Omachi, N. ... Atagi, S. (2017). Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors. Oncology Letters, 14, 7589-7596. https://doi.org/10.3892/ol.2017.7125
MLA
Taniguchi, Y., Tamiya, A., Nakahama, K., Naoki, Y., Kanazu, M., Omachi, N., Okishio, K., Kasai, T., Atagi, S."Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors". Oncology Letters 14.6 (2017): 7589-7596.
Chicago
Taniguchi, Y., Tamiya, A., Nakahama, K., Naoki, Y., Kanazu, M., Omachi, N., Okishio, K., Kasai, T., Atagi, S."Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitors". Oncology Letters 14, no. 6 (2017): 7589-7596. https://doi.org/10.3892/ol.2017.7125